Pan-RAF Inhibitor Composition for Class II and III BRAF Mutations

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current BRAF inhibitors are ineffective against Class II and III BRAF mutations, which are prevalent in a significant proportion of cancers, leaving these patient populations with unmet clinical needs.

Innovation Solution

Development of a heterocyclic RAF inhibitor, Compound 1, which is a reversible small molecule inhibitor effective against all classes of BRAF mutations, including Class II and III, by targeting RAF kinases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current BRAF inhibitors are used, then Class I BRAF mutations are inhibited, but Class II and III BRAF mutations remain ineffective

Engineering Contradiction:

Improveeffectiveness against BRAF mutationsVSAvoidcoverage of different BRAF mutation classes

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent develops a RAF inhibitor that performs multiple functions by effectively inhibiting all three classes of BRAF mutations (Class I, II, and III), transforming a mutation-specific inhibitor into a universal inhibitor that addresses diverse genetic alterations across different cancer types.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention modifies the chemical structure and binding parameters of the inhibitor to achieve broader specificity, changing the molecular characteristics to accommodate different mutation classes while maintaining inhibitory efficacy across all variants.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If conventional RAF inhibitors are used, then some cancer types are treated, but relapsed and refractory patients have unmet clinical needs

Engineering Contradiction:

Improvetherapeutic response rateVSAvoiddurability of response in relapsed/refractory patients

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent introduces a novel RAF inhibitor as an intermediary therapeutic agent that bridges the gap for patients who have exhausted conventional treatment options, providing a new mechanism of action that overcomes resistance developed to previous inhibitors.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12569496B2Treatment of cancer with a RAF inhibitor

Publication Date: 2026.03.10 PIERRE FABRE MEDICAMENT SAS

AI summary

Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.